Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eusa Pharma has out-licensed the exclusive world-wide rights of its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline or GSK for a consideration of up to $44 million, comprising an upfront fee and development milestones, plus royalties on future sales.
Subscribe to our email newsletter
As part of the agreement Eusa will pay approximately 50% of the overall consideration to its development partner for the antibody, Vaccinex. GSK will fund and conduct all future development, production and commercialization of the product. Eusa’s product, OP-R003, is said to be the first fully human anti-interleukin-6 antibody, with target indications in oncology and inflammatory diseases.
Brian McVeigh, GSK’s worldwide business development director of M&A Strategy and Transactions, said: “Interleukin-6 is increasingly recognized as an important biological target in a range of diseases, and consequently OP-R003 has great potential to meet a number of unmet medical needs.”